| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| LET | lidocaine, epinephrine, and tetracaine [solution]; linear or low energy transfer |
|---|---|
| VF | 1) Ventricular Fibrillation ? Tx of Ventricular Fibrillation ... |
| WPW Syndrome | Wolff-Parkinson-White Syndrome ? CIx 1. Drugs; AV Conduct... |
| BL | Barre-Lieou [syndrome]; basal lamina; baseline; Bessey-Lowry [unit]; black light; bladder; bleeding;... |
| BLE | both lower extremities; buffered lidocaine with epinephrine |
| L | Lidocaine |
|---|---|
| LID | Lidocaine |
| xylocaine | Lidocaine |
| lidocaine | Lignocaine |
| LIDO | lidocaine |
oral (°æ±¸, ÀÔÀÇ, °æ±¸ÀÇ, ±¸°, ±¸°ÀÇ
acute angle
| prilocaine | <chemical> A local anaesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anaesthesia in dentistry. Pharmacological action: anaesthetics, local. Chemical name: Propanamide, N-(2-methylphenyl)-2-(propylamino)- (12 Dec 1998) |
|---|---|
| prilocaine hydrochloride | 2-(propylamino)-o-propionotoluidide hydrochloride;a local anaesthetic of the amide type, related chemically and pharmacologically to lidocaine hydrochloride; used for peridural, caudal, and nerve blocks, and for regional and infiltration anaesthesia. Synonym: propitocaine hydrochloride. (05 Mar 2000) |
| lidocaine | <cardiology, drug> A local anaesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. Pharmacological action: anaesthetics, local, anti-arrhythmia agents. Decreases automaticity, depresses conduction in reentrant pathways and may raise fibrillation threshold, especially in combination with bretylium. Uses: The drug of first choice for ventricular arrhythmias, ventricular ectopy, and wide complex tachycardias of unknown origin. Dose: 1-1.5 mg/kg IV bolus, followed by additional 0.5-1.5 mg/kg every 5-10 min to a total of 3 mg/kg. Can be administered via the endotracheal tube. Use 2 to 2.5 times the intravenous dose. Upon return of circulation, use continuous infusion at 2 - 4 mg/min. Reduce the maintenance dose if decreased cardiac output or hepatic failure or more than 70 years of age. Potential complications: dizziness, drowsiness, disorientation, seizures, hypotension - causes vasodilation; myocardial depression at higher concentrations; heart block - only rarely seen with high levels. Chemical name: 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide (15 Mar 2000) |
| lidocaine N-deethylase | <enzyme> Catalyzed mainly by cytochrome p-450 3a2 in rat liver microsomes Registry number: EC 1.- (26 Jun 1999) |
| abstracting and indexing | Shortening or summarizing of documents; assigning of descriptors for referencing documents. (12 Dec 1998) |
| academies and institutes | Organizations representing specialised fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., national academy of sciences, brookings institution, etc. (12 Dec 1998) |
| accounts payable and receivable | Short-term debt obligations and assets occurring in the regular course of operational transactions. (12 Dec 1998) |
| aged, 80 and over | A person 80 years of age and older. (12 Dec 1998) |
| algae and fungi | Algae represent a group of spore-propagating plants, unicellular or undifferentiated into root, stem, and leaf. They include seaweed and many unicellular fresh water plants, most of which contain chlorophyll. They account for about 90% of the earth's photosynthetic activity. Fungi are eukaryotic, heterotrophic organisms that live as saprobes or parasites and include mushrooms, yeasts, smuts, molds, etc. They lack chlorophyll. (12 Dec 1998) |
| alkyl and aryl transferases | <enzyme> A somewhat heterogeneous class of enzymes that catalyze the transfer of alkyl or related groups (excluding methyl groups). Registry number: EC 2.5 (12 Dec 1998) |
| allergy and immunology | A medical specialty concerned with the hypersensitivity of the individual to foreign substances and protection from the resultant infection or disorder. (12 Dec 1998) |
| alligators and crocodiles | Large, long-tailed reptiles, including caimans, of the order loricata. (12 Dec 1998) |
| Amine Precursor Uptake and Decarboxylation | <pharmacology, physiology> Paracrine cells of which argentaffin cells are an example. Usage of the term APUD is neither helpful nor memorable. Acronym: APUD (11 Nov 1997) |
| amino acids, peptides, and proteins | Amino acids and chains of amino acids connected by peptide linkages. (12 Dec 1998) |
| Anderson and Goldberger test | A test for typhus in which the patient's blood is injected into a guinea pig's peritoneal cavity. In typhus a typical temperature curve will be observed. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|